Navigation Links
Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction With The American Society of Hematology 48th Annual Meeting
Date:12/3/2007

SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that that it will hold an analyst and investor briefing in conjunction with The American Society of Hematology 48th Annual Meeting from 8:00 p.m. to 9:00 p.m. ET on Monday, December 10, 2007.

The event will be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

Speakers:

-- Michael Morrissey, PhD, President of Research & Development of

Exelixis, Inc.

-- Gisela Schwab, MD, Senior Vice President & Chief Medical Officer of

Exelixis, Inc.

-- Ruben Mesa, MD of the Mayo Clinic

An archive of this webcast will be available until 9:00 p.m. PT/12:00 a.m. ET on January 9, 2008. Access numbers for this replay are: 1-888-286-8010 (domestic) and +1-617-801-6888 (international); the replay passcode number is: 63491998.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For mo
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Exelixis Commences Public Offering of Common Stock
2. Exelixis Announces September 18 Webcast of Presentation at the Bank of America 2007 Investment Conference
3. Exelixis Announces October 10 Webcast of Presentation at the 2007 Bio InvestorForum Conference
4. Exelixis Announces November 6 Webcast of Presentation at the CIBC World Markets 18th Annual Healthcare Conference
5. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... Armadale Capital ... announced the closing of a $118 million FHA-insured loan modification refinancing for Johnston ... Smithfield and Clayton, North Carolina. JHSC is a joint venture of Johnston ...
(Date:8/4/2015)... ... August 04, 2015 , ... Oriental Trading Company, ... toys, novelties, and school supplies, has developed engaging and affordable teacher supplies based ... includes student rewards, classroom decorations, crafts and educational resources featuring Carle’s vibrant ...
(Date:8/4/2015)... ... 2015 , ... It is National Psoriasis Awareness Month, and we are reminded ... as dry, itching, burning or soreness of skin that may crack or bleed. , ... what’s right for them. Then, what is effective may stop working, so they have ...
(Date:8/4/2015)... ... ... The goal of looking younger – with a fresher, more rested appearance ... ideal is not. But minimally invasive procedures such as dermal fillers, tighteners or laser ... time, according to Valerie Goldburt, MD, PhD , of Advanced Dermatology P.C. ...
(Date:8/4/2015)... ... August 04, 2015 , ... Nathan’s Famous was recently featured ... medium, and large businesses making an impact in their industry. Andrew Tropeano, the host ... the famous hot dog maker now offers a 50% Reduced Fat All-Beef Frank ...
Breaking Medicine News(10 mins):Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 3Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 2Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 3
... and ,Samantha Who?, to be Honored at Donate Life Film ... June 5 On June 13, Donate Life Hollywood will ... "Samantha Who?" with its first annual Inspire Award. This honor, ... be presented at the culmination of the daylong Donate Life ...
... evident with seniors, researchers say , FRIDAY, June 5 (HealthDay ... new generation of video games that require users to get ... bit more fit. , New research suggests that several exercise-based ... equal to that of light jogging. , And seniors in ...
... Joseph F. Finn, Jr., C.P.A. ("Finn") announced today ... Cancer Research Ltd., Brussels Branch. The statement is quoted ... product candidate, GCS-100, is a carbohydrate molecule which inhibits the ... a broad range of human cancers. Prospect reported that ...
... show, , FRIDAY, June 5 (HealthDay News) -- One reason ... not that interesting. But what if you could dance your ... suggest that you just might be able to do that. ... meeting in Seattle, one study found that salsa dancing could ...
... region are ready to prescribe and dispense medications electronically , ... of Spain and IBM (NYSE: IBM ) have ... where health centres and pharmacies are now computerised and able ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090416/IBMLOGO ...
... are experiencing onerous fatigue four months after the infarction. The ... infarction as a sign of chronic illness, those who experience ... that the illness has a large impact on their life. ... Sahlgrenska Academy, University of Gothenburg, Sweden. Just over 200 ...
Cached Medicine News:Health News:ABC-TV Gets It Right According to Organ Donation Community 2Health News:Interactive Video Games Offer Exercise Benefits 2Health News:Interactive Video Games Offer Exercise Benefits 3Health News:Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Inc's. GCS-100 Molecule 2Health News:Finding Fitness on the Dance Floor 2Health News:Finding Fitness on the Dance Floor 3Health News:Spain's Regional Extremadura Government Launches Electronic Prescription System With IBM 2Health News:Fatigue common after myocardial infarction 2
(Date:8/3/2015)... Pa. , Aug. 3, 2015 ... specialty biotechnology company focused on developing aerosolized KL4 ... live teleconference and webcast at 8:30 a.m. Eastern Time ... management will discuss the 2015 second quarter financial ... company will issue a press release announcing the ...
(Date:8/3/2015)... 3, 2015 Your doctor has recommended surgery ... for the best possible outcome. Your orthopaedic foot and ... and now there,s a three-part online series ... the American Orthopaedic Foot & Ankle Society (AOFAS) ... avoid complications and heal as quickly as possible. ...
(Date:8/3/2015)... SAN FRANCISCO , Aug. 3, 2015  Sage ... generation of portable laboratory-quality cannabis potency measurement systems, announced ... PAC Bay Area Cruise Fundraiser. A limited number of ... the festivities and help a great cause while enjoying ... a scenic cruise around the San Francisco Bay at ...
Breaking Medicine Technology:Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2Patient Guide: How to Prepare for Surgery 2Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2
... 1, 2011 PTC Therapeutics, Inc. (PTC) today announced ... of ataluren, an investigational new drug, in adults with ... Respiratory Journal . The published three-month data showed that ... chloride channel activity, CF-related cough and positive trends in ...
... READING, England and BEDMINSTER, N.J., June 30, 2011 ... Inc., today announced that the U.S. Food and Drug ... the management of breakthrough pain in cancer patients 18 ... and who are tolerant to opioid therapy for their ...
Cached Medicine Technology:Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 2Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 3Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 4Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 5Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 6FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 2FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 3FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 4FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 5FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 6FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 7FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 8